Serum (32-microgiobulin decreases in patients with aids or arc treated with azidothymidine

Mark A. Jacobson, Donald I. Abrams, Paul A. Volberding, Peter Bacchetti, Judith Wilber, Richard E. Chaisson, Suzanne Crowe, Walter Howard, Andrew Moss

Research output: Contribution to journalArticlepeer-review

Abstract

Abnormally elevated serum p2-microglobulin has been associated with progression of human immunodeficiency virus (HIV) disease and could reflect in vivo HIV activity. We prospectively studied the effect of azidothymidine therapy on serum p2-microglobulin concentration in 41 patients with AIDS or AIDS-related complex. Median p2-microglobuIin concentration decreased from 4.02 mg/L before therapy to 3.73 mg/L at week 24 of therapy (P =.016). Individual changes in p2-microglobulin during azidothymidine therapy correlated with changes in serum HIV p24 antigen (Spearman, r =.42, P =.007). Also, in a randomized placebo-controlled study, median [)2-microglobulin concentration decreased after 16 w of therapy in 5 azidothymidine-treated patients compared with levels in 7 placebo-treated controls (P =.05). Serum p2-microglobulin appears to be a sensitive marker for in vivo antiretroviral drug activity and may be a better marker than serum p24 antigen for early intervention trials involving antiretroviral agents.

Original languageEnglish (US)
Pages (from-to)1029-1036
Number of pages8
JournalJournal of Infectious Diseases
Volume159
Issue number6
DOIs
StatePublished - Jun 1989
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Serum (3<sub>2</sub>-microgiobulin decreases in patients with aids or arc treated with azidothymidine'. Together they form a unique fingerprint.

Cite this